![]() ![]() "The safety and efficacy of Pradaxa has already been well-established, and these sub-analyses add to the growing body of evidence on its clinical impact in patients with atrial fibrillation."ĭetails of the data presented at the AHA Scientific Sessions 2017 are as follows: "We look forward to sharing important new insights about Pradaxa and idarucizumab from RE-DUAL PCI™, RE-CIRCUIT™ and RE-VERSE AD™, three pivotal trials that have all been published in the New England Journal of Medicine this year," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. In total, five abstracts investigating Pradaxa® (dabigatran etexilate mesylate) and its reversal agent, idarucizumab, marketed in the U.S. ![]() 10, 2017 /PRNewswire/ - Boehringer Ingelheim today announced that important sub-analyses from three major trials in anticoagulation care will be presented at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, California, November 11-15.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |